glp-1 parkinson's disease Repurposing Receptor Agonists for Disease: Current Evidence and Future Opportunities | Pharmaceutical Medicine glp 1 neuroprotection Beyond insulin:

Currently, approximately 40 million patients in the US have insurance coverage for Wegovy--30 million via commercial health insurance, and the remaining through Medicaid

BPC-157 has been shown to: Increase fibroblast recruitment Speed up collagen deposition Improve tendon-to-bone interface healing Reinforce ligament remodeling after trauma This makes it highly effective for: Partial tendon tears Post-surgical repair Muscle strains and chronic tendonitis Application of BPC-157 significantly improved fibroblast activity and collagen fiber orientation in Achilles tendon repair models. Chang et al., American Journal of Sports Medicine 3

Oral Semaglutide was approved by the FDA in 2019 as the first oral GLP-1 receptor agonist for type 2 diabetes

The plaintiffs filed an amended complaint June 8 expanding that theory

Pfizer lead asset after Metsera acquisition is also in phase 3